Position in RPRX
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$23,825,835
+$3,702,780 QoQ
Shares Held
496,682
-4.6% QoQ
Ownership
0.086%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ALPS ADVISORS INC holds $156,743,120 across 93 Biotechnology names. RPRX ranks #1 (15.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
This page
|
496,682 | $23,825,835 | |
| 2 | KYMR |
Kymera Therapeutics, Inc.
|
66,457 | $5,535,203 | |
| 3 | CGON |
CG Oncology, Inc.
|
68,737 | $4,652,120 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
49,128 | $4,538,444 | |
| 5 | CELC |
Celcuity Inc.
|
37,663 | $4,298,854 | |
| 6 | APLS |
Apellis Pharmaceuticals, Inc.
|
104,058 | $4,186,253 | |
| 7 | XENE |
Xenon Pharmaceuticals Inc.
|
67,723 | $3,938,092 | |
| 8 | APGE |
Apogee Therapeutics, Inc.
|
45,586 | $3,836,973 |
All Filings in RPRX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $23,825,835 | 496,682 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $20,123,055 | 520,783 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $19,514,214 | 553,124 | Shares | Defined | 2025-11-05 | |
| 2024-06-30 | $302,938 | 11,488 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $350,773 | 11,550 | Shares | Defined | 2024-05-14 | |
| 2021-06-30 | $296,439 | 7,232 | Shares | Defined | 2021-08-11 | |
| 2021-03-31 | $315,459 | 7,232 | Shares | Defined | 2021-05-07 | |
| No filing history on record for this holder in this stock. | ||||||